Full-Time

Senior Software Engineer

Applied AI

Confirmed live in the last 24 hours

Formation Bio

Formation Bio

51-200 employees

Accelerates drug development using AI technology

Compensation Overview

$180k - $230k/yr

+ Equity + Comprehensive Benefits

Senior

New York, NY, USA

Candidates must reside in New York City, Boston metro areas, Research Triangle (NC), or San Francisco Bay Area, or be willing to relocate.

Category
Backend Engineering
Software QA & Testing
Software Engineering
Required Skills
Microsoft Azure
Python
Tensorflow
Pytorch
AWS
Reinforcement Learning
Google Cloud Platform
Requirements
  • Master’s degree in Computer Science, Engineering, Mathematics, or a related field, or equivalent experience.
  • 6+ years of experience in software development and applied ML, with a focus on building predictive models, ranking systems, and risk assessment pipelines.
  • Proven track record of designing, deploying, and maintaining ML and LLM models in production environments, including experience with versioning, scaling, and monitoring.
  • Demonstrated ability to drive measurable business impact with ML and LLM solutions — from defining success metrics to iterating based on real-world feedback.
  • Strong foundation in supervised, unsupervised, and reinforcement learning, as well as LLM techniques such as prompt engineering, retrieval-augmented generation (RAG), and fine-tuning.
  • Proficient in Python, with deep experience in libraries such as TensorFlow, PyTorch etc
  • Experience working with large-scale data pipelines and deploying ML models in cloud environments (AWS, GCP, or Azure).
  • Familiarity with model evaluation techniques, including cross-validation, A/B testing, and confidence-based ranking.
  • Experience building multi-agent AI systems, including listener/orchestrator agents for dynamic data ingestion and decision-making.
  • Excellent communication skills, with the ability to explain technical concepts to non-technical stakeholders and align teams around complex solutions.
Responsibilities
  • Lead the design, development, and deployment of machine learning models for classification, recommendation, and risk assessment to enhance decision-making in drug development.
  • Build and optimize predictive models, including classification, regression, time-series, and ranking algorithms, with a focus on robust deployment in production environments.
  • Collaborate with cross-functional teams — including data scientists, engineers, and drug development stakeholders to design and deliver high-impact ML solutions.
  • Work with large-scale proprietary datasets (e.g., SPOKE, Evaluate data, KOL transcripts), ensuring performance benchmarks are met within cloud-based infrastructure (AWS, GCP, Azure).
  • Rapidly prototype and iterate on machine learning solutions, including proofs-of-concept, to explore innovative approaches and evaluate business impact.
  • Integrate structured knowledge into ML pipelines using ontologies and document store architectures, enhancing model context and data retrieval.
  • Design and build AI-driven listener agents that continuously ingest new information and trigger reanalysis of drug candidates using updated predictive models.
  • Stay current with emerging trends in machine learning and generative AI, applying them to continuously evolve our modeling and decision-making capabilities.
Desired Qualifications
  • Experience in the pharmaceutical or biotech industry is a plus, but not required.

Formation Bio focuses on speeding up the process of developing new drugs by using its own technology platform that incorporates artificial intelligence. The company specifically looks for clinical-stage assets, which are drugs that are already in testing phases, and works on acquiring and developing them through adaptable financial strategies. By doing this, Formation Bio aims to lower the high costs and long timelines that are usually involved in bringing new medications to market, making them more affordable and accessible to patients. Unlike many other companies in the pharmaceutical and biotech industries, Formation Bio emphasizes the use of advanced AI tools to improve the selection and development of drugs, which helps increase efficiency in the drug development process. The ultimate goal of Formation Bio is to successfully commercialize drugs and form partnerships that will benefit both the company and the healthcare industry.

Company Size

51-200

Company Stage

Series D

Total Funding

$530.3M

Headquarters

New York City, New York

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Formation Bio raised $372M in Series D funding for expansion and development.
  • Partnership with Sanofi and OpenAI enhances AI-driven drug discovery capabilities.
  • Entrepreneurs in Residence program boosts business development and strategic partnerships.

What critics are saying

  • Increased competition from AI-driven pharma companies may impact market share.
  • Rapid AI advancements could render Formation Bio's platform obsolete if not updated.
  • Regulatory scrutiny on AI-driven processes could delay product approvals and increase costs.

What makes Formation Bio unique

  • Formation Bio uses AI to accelerate drug development and reduce costs.
  • The company acquires clinical-stage assets for faster development and commercialization.
  • Formation Bio's platform optimizes trial design and execution for higher success rates.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
PR Newswire
Jun 9th, 2025
Formation Bio Announces First Class Of Entrepreneurs In Residence To Drive Pipeline Growth And Strategic Partnerships

NEW YORK, June 9, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company focused on accelerating drug development, today announced the appointment of its first class of Entrepreneurs in Residence (EIRs): Kia Motesharei, Ph.D., Minji Kim Ph.D, MBA, John Taylor, M.S., and Anthony S. Walsh, D.Phil, These seasoned dealmakers will work closely with Chief Business Officer David Steinberg to expand the company's business development capabilities and further its mission to bring high-potential treatments to patients faster. Formation Bio acquires and in-licenses promising drug assets, advancing them through critical development milestones (Phase II and beyond), and then out-licensing for further advancement. The company's AI platform supports this lifecycle end-to-end—from asset identification and development strategy to execution of clinical trials aimed at greater speed and higher probability of success

Intelligence360
Jul 18th, 2024
Trialspark Dba Formation Bio Has Filed A Notice Of An Exempt Offering Of Securities To Raise $372,000,000.00 In New Equity Investment.

TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment. TrialSpark dba Formation Bio has filed a notice of an exempt offering of securities to raise $372,000,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, TrialSpark dba Formation Bio is raising up to $372,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Benjamine Liu played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TrialSpark dba Formation BioFormation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.To learn more about TrialSpark dba Formation Bio, visit http://www.formation.bio/TrialSpark dba Formation Bio Linkedin Page: https://www.linkedin.com/company/formationbio/Contact:Benjamine Liu, Chief Executive Officer866-283-7544https://www.linkedin.com/in/benjamine-liu-54306518/SOURCE: http://www.intelligence360.ioCopyright (c) 2024 SI360 Inc

Finsmes
Jun 26th, 2024
Formation Bio Raises $372M in Series D Funding

Formation Bio, a NYC-based tech-driven and AI-native pharma company, raised $372M in Series D funding

Hit Consultant
May 21st, 2024
Sanofi, Formation Bio, Openai Partner On Ai-Powered Drug Discovery

What You Should Know:– Sanofi, a global pharmaceutical leader, Formation Bio, an AI-powered drug developer, and OpenAI, a leading research and development company in artificial intelligence, have announced a groundbreaking collaboration. The first-of-its-kind partnership in the pharma and life sciences industries aims to leverage AI to accelerate drug development and bring new medicines to patients faster.– Sanofi, Formation Bio, and OpenAI believe this collaboration will be a game-changer in the pharmaceutical industry. By combining their expertise in data, AI technology, and drug development, they aim to revolutionize the way new medicines are discovered and brought to market.A Symphony of ExpertiseThe collaboration will combine the unique strengths of each partner:Sanofi: Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery.Will contribute proprietary data for building custom AI models, furthering their goal of becoming the first biopharma company powered by AI at scale. This data will be crucial for training and refining the AI tools used in drug discovery. OpenAI: World-renowned for its advancements in AI technology, OpenAI will contribute access to cutting-edge AI capabilities

PR Newswire
Jan 10th, 2022
Trialspark partners with SomaLogic, Inc.

TrialSpark is also partnering with industry leaders such as SomaLogic to leverage precision genomics and proteomics platforms to identify key biomarkers and stratify patients using synovial fluid samples from prior clinical studies using AI and machine-learning approaches.